ArticleIrish journal of medical science2025
Evaluating plasma phoenixin-14, galanin, galanin-like peptide, and spexin levels in polycystic ovary syndrome.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImpaired central neuropeptide production is implicated in polycystic ovary syndrome (PCOS).
aimThis study aimed to determine whether plasma phoenixin-14, galanin (GAL), galanin-like peptide (GALP), and spexin levels in women with PCOS were altered compared to those in non-PCOS controls.
methodsSixty participants, including 30 patients diagnosed with PCOS and 30 healthy controls, were enrolled in this study. Phoenixin-14, GAL, GALP, and spexin levels were measured in plasma samples.
resultsAlthough plasma phoenixin-14 levels in the PCOS group were significantly higher than those in the control group, spexin and GAL levels were significantly lower. No significant intergroup differences were observed in plasma GALP levels (p = 0.442). To distinguish PCOS from healthy controls, the area under the receiver operating characteristic (ROC) curve (AUC) of phoenixin-14 was 0.798, that of spexin was 0.757, and that of GAL was 0.702 (p < 0.001, p < 0.001, and p = 0.003, respectively). The AUC of the combined diagnostic value of the three peptides for PCOS was 0.910 (95%CI: 0.808-0.968) (p < 0.001), indicating a good diagnostic value.
conclusionsPlasma phoenixin-14, spexin, and GAL levels differed between patients with PCOS and controls. When combined, the three peptides exhibited better predictive performance than the individual peptides.
Indexed as
Identifiers
40991186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.